FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol
The US Food and Drug Administration (FDA) approved the first oral protein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to reduce low-density lipoprotein (LDL) cholesterol. PCSK9 inhibitors have previously been available only as injectable therapies.
Original Source
Read the full article at Jamanetwork →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.